Search results for "scandium-44"

showing 6 items of 6 documents

Gallium-68 and scandium-44 labelled radiotracers based on curcumin structure linked to bifunctional chelators: Synthesis and characterization of pote…

2019

Abstract Curcumin metal complexes showed widespread applications in medicine and can be exploited as a lead structure for developing new tracers for nuclear medicine application. Herein, the synthesis, chemical characterization and radiolabelling with gallium-68 and scandium-44 of two new targeting vectors based on curcumin scaffolds and linked to the chelators 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA) and 1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-methylperhydro-1,4-diazepine (AAZTA) are reported. Synthesis of the precursors could be achieved with a 13% and 11% yield and radiolabelling generally afforded rapid incorporation under mild conditions (>95%). Sta…

CurcuminRadionuclide imagingGallium RadioisotopesPyrazole010402 general chemistry01 natural sciencesBiochemistryInorganic Chemistrychemistry.chemical_compoundMoietyAnimalsHumansTissue DistributionRadioactive TracersBifunctionalDerivatizationPET radiopharmaceuticalsChelating AgentsRadioisotopes010405 organic chemistryGallium-68Combinatorial chemistryIn vitro0104 chemical scienceschemistryYield (chemistry)Positron-Emission TomographyLipophilicityNuclear medicineCurcuminCurcumin; Gallium-68; Nuclear medicine; PET radiopharmaceuticals; Radionuclide imaging; Scandium-44RadiopharmaceuticalsScandium-44Scandium
researchProduct

Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer

2017

Background: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications. In this context, the positron emitter scandium-44 is an attractive alternative for PET imaging. We report the synthesis of [44Sc…

OncologyMalemedicine.medical_specialtytheranostics.Medicine (miscellaneous)Context (language use)SpleenGallium RadioisotopesLutetiumurologic and male genital diseases030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancerHeterocyclic Compounds 1-Ring0302 clinical medicineInternal medicinePositron Emission Tomography Computed TomographyLNCaPmedicineDosimetryHumansRadiometryPharmacology Toxicology and Pharmaceutics (miscellaneous)AgedRadioisotopesUrinary bladderChemistrybusiness.industryDipeptidesProstate-Specific Antigenmedicine.diseaseprostate cancerPSMA-617scandium-44Small intestineProstatic Neoplasms Castration-Resistantmedicine.anatomical_structurePET030220 oncology & carcinogenesisAbsorbed doseRadiopharmaceuticalsNuclear medicinebusinessScandiumResearch PaperHalf-LifeTheranostics
researchProduct

In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi

2021

Recently, the first squaramide-(SA) containing FAP inhibitor-derived radiotracers were introduced. DATA5m.SA.FAPi and DOTA.SA.FAPi with their non-radioactive complexes showed high affinity and selectivity for FAP. After a successful preclinical study with [68Ga]Ga-DOTA.SA.FAPi, the first patient studies were realized for both compounds. Here, we present a new squaramide-containing compound targeting FAP, based on the AAZTA5 chelator 1,4-bis-(carboxylmethyl)-6-[bis-(carboxymethyl)-amino-6-pentanoic-acid]-perhydro-1,4-diazepine. For this molecule (AAZTA5.SA.FAPi), complexation with radionuclides such as gallium-68, scandium-44, and lutetium-177 was investigated, and the in vitro properties of…

PREPPharmaceutical ScienceAcetatesLutetiumLigands030218 nuclear medicine & medical imagingAnalytical ChemistrySerinechemistry.chemical_compoundQD241-4410302 clinical medicineFibroblast activation protein alphaPositron Emission Tomography Computed TomographyDrug Discoverylutetium-177AAZTA; scandium-44; lutetium-177; FAP; SA; DPP; PREPQuinineChemistrySerine EndopeptidasesAzepinesscandium-44ChemistryChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineSelectivityDPPGallium RadioisotopesConjugated systemArticleHeterocyclic Compounds 1-Ring03 medical and health sciencesSAEndopeptidasesHumansDOTAChelationPhysical and Theoretical ChemistryBiologyAAZTARadioisotopesOrganic ChemistrySquaramideMembrane ProteinsFAPFibroblastsCombinatorial chemistryIn vitroRadiopharmaceuticalsScandiumMolecules
researchProduct

Image quality analysis of

2019

Background 44Sc has been increasingly investigated as a potential alternative to 68Ga in the development of tracers for positron emission tomography (PET). The lower mean positron energy of 44Sc (0.63 MeV) compared to 68Ga (0.83 MeV) can result in better spatial image resolutions. However, high-energy γ-rays (1157 keV) are emitted at high rates (99.9%) during 44Sc decay, which can reduce image quality. Therefore, we investigated the impact of these physical properties and performed an unbiased performance evaluation of 44Sc and 68Ga with different imaging phantoms (image quality phantom, Derenzo phantom, and three-rod phantom) on two preclinical PET scanners (Mediso nanoScan PET/MRI, Siemen…

Positron rangeSmall animal PETImage qualityPositron energyPhantom studyScandium-44ResolutionOriginal ResearchEJNMMI physics
researchProduct

Evaluation of the inverse electron demand Diels-Alder reaction in rats using a scandium-44-labelled tetrazine for pretargeted PET imaging

2019

Background Pretargeted imaging allows the use of short-lived radionuclides when imaging the accumulation of slow clearing targeting agents such as antibodies. The biotin-(strept)avidin and the bispecific antibody-hapten interactions have been applied in clinical pretargeting studies; unfortunately, these systems led to immunogenic responses in patients. The inverse electron demand Diels-Alder (IEDDA) reaction between a radiolabelled tetrazine (Tz) and a trans-cyclooctene (TCO)-functionalized targeting vector is a promising alternative for clinical pretargeted imaging due to its fast reaction kinetics. This strategy was first applied in nuclear medicine using an 111In-labelled Tz to image TC…

lcsh:Medical physics. Medical radiology. Nuclear medicineBiodistributionlcsh:R895-920Tetrazine010402 general chemistry01 natural sciencesChemical kineticsTetrazinechemistry.chemical_compoundMedicineDOTARadiology Nuclear Medicine and imagingPretargeted imagingInverse electron-demand Diels–Alder reactionAlendronic acidOriginal ResearchPretargetingTrans-cyclooctene (TCO)biologymedicine.diagnostic_test010405 organic chemistrybusiness.industryScandium-44 (44Sc)RadiochemistryBisphosphonates0104 chemical sciences3. Good healthchemistryPositron emission tomographyPositron emission tomography (PET)biology.proteinInverse electron demand Diels-Alder (IEDDA)businessAvidinEJNMMI Research
researchProduct

Labeling of DOTA-conjugated HPMA-based polymers with trivalent metallic radionuclides for molecular imaging.

2017

Background In this work, the in vitro and in vivo stabilities and the pharmacology of HPMA-made homopolymers were studied by means of radiometal-labeled derivatives. Aiming to identify the fewer amount and the optimal DOTA-linker structure that provides quantitative labeling yields, diverse DOTA-linker systems were conjugated in different amounts to HPMA homopolymers to coordinate trivalent radiometals Me(III)* = gallium-68, scandium-44, and lutetium-177. Results Short linkers and as low as 1.6% DOTA were enough to obtain labeling yields > 90%. Alkoxy linkers generally exhibited lower labeling yields than alkane analogues despite of similar chain length and DOTA incorporation rate. High sta…

lcsh:Medical physics. Medical radiology. Nuclear medicinelcsh:R895-920Gallium-68610 MedizinDOTA-HPMA conjugatesPETBiodistributionTheranostic610 Medical sciencesScandium-44Lutetium-177neoplasmsOriginal ResearchRadiolabelingEJNMMI research
researchProduct